Trial
NCT04001231
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
—
Condition
Type 2 Diabetes
Intervention
Exenatide Once-Weekly Suspension
Why stopped
The study is stopped based upon strategic considerations impacting the clinical development of exenatide once-weekly suspension in China
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-04